Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
University of Cincinnati, Division of Internal Medicine
mi
from
Cincinnati, OH
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
University of Cincinnati, Division of Internal Medicine
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Optimed Research, LTD
mi
from
Columbus, OH
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Optimed Research, LTD
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Asthma Allergy & Pulmonary Associates
mi
from
Philadelphia, PA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Asthma Allergy & Pulmonary Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Highlands Allergy and Asthma Center, PC
mi
from
Bristol, TN
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Highlands Allergy and Asthma Center, PC
mi
from
Bristol, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
The Paull Allergy and Asthma Clinic, P.A.
mi
from
Bryan, TX
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
The Paull Allergy and Asthma Clinic, P.A.
mi
from
Bryan, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
AARA Research Center
mi
from
Dallas, TX
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
AARA Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Puget Sound Allergy, Asthma & Immunology
mi
from
Tacoma, WA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Puget Sound Allergy, Asthma & Immunology
mi
from
Tacoma, WA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Allergy and Asthma Research Centre
mi
from
Ottawa,
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Allergy and Asthma Research Centre
mi
from
Ottawa,
Click here to add this to my saved trials
Assessment of the Potential for Pressure Ulcer Formation
Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging
Status: Enrolling
Updated:  2/12/2018
UCIMC
mi
from
Orange, CA
Assessment of the Potential for Pressure Ulcer Formation
Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging
Status: Enrolling
Updated: 2/12/2018
UCIMC
mi
from
Orange, CA
Click here to add this to my saved trials
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Status: Enrolling
Updated:  2/15/2018
Pavilion Dermatology Suite K
mi
from
Jackson, MS
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Status: Enrolling
Updated: 2/15/2018
Pavilion Dermatology Suite K
mi
from
Jackson, MS
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative site
mi
from
Los Angeles, CA
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
mi
from
Atlanta, GA
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
mi
from
Ann Arbor, MI
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
mi
from
Buffalo, NY
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
mi
from
Durham, NC
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis
mi
from
Pittsburgh, PA
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
mi
from
Salt Lake City, UT
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
mi
from
Kogarah,
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
mi
from
Kogarah,
Click here to add this to my saved trials
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.
Status: Enrolling
Updated:  3/14/2018
R Adams Cowley Shock Trauma Center, U. of Maryland Medical Center
mi
from
Baltimore, MD
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.
Status: Enrolling
Updated: 3/14/2018
R Adams Cowley Shock Trauma Center, U. of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Emory University
mi
from
Atlanta, GA
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
David Fivenson, M.D. Dermatology, PLLC
mi
from
Ann Arbor, MI
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
David Fivenson, M.D. Dermatology, PLLC
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Wright State University School of Medicine
mi
from
Dayton, OH
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Wright State University School of Medicine
mi
from
Dayton, OH
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Oregon Health and Science University
mi
from
Portland, OR
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
University of Louisville
mi
from
Louisville, KY
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Tufts - New England Medical Center
mi
from
Boston, MA
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Tufts - New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
University of Michigan
mi
from
Ann Arbor, MI
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
University Hospitals of Cleveland
mi
from
Cleveland, OH
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Providence VA Medical Center, Providence, RI
mi
from
Providence, RI
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Providence VA Medical Center, Providence, RI
mi
from
Providence, RI
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
mi
from
Denver, CO
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
mi
from
Denver, CO
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
mi
from
Bay Pines, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
mi
from
Bay Pines, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy and Asthma Relief Experts
mi
from
Granada Hills, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy and Asthma Relief Experts
mi
from
Granada Hills, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy & Asthma Care Center of Southern California
mi
from
Long Beach, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy & Asthma Care Center of Southern California
mi
from
Long Beach, CA
Click here to add this to my saved trials